Rallybio (RLYB) Expected to Announce Quarterly Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Rallybio to post earnings of ($1.44) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Rallybio (NASDAQ:RLYB) last released its earnings results on Tuesday, October 27th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative return on equity of 31.44%.

Rallybio Trading Up 1.4%

RLYB stock opened at $15.76 on Tuesday. Rallybio has a 12 month low of $3.67 and a 12 month high of $17.57. The company has a 50-day moving average price of $16.71 and a 200 day moving average price of $12.92. The stock has a market cap of $84.85 million, a PE ratio of -3.63 and a beta of -0.72.

Rallybio Dividend Announcement

The company also recently disclosed a special dividend, which will be paid on Friday, November 13th. Investors of record on Thursday, November 5th will be given a $13.56 dividend.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on RLYB shares. Wall Street Zen upgraded Rallybio from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Weiss Ratings cut Rallybio from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Rallybio Company Profile

Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.

Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.